John R. Perfect, MD
Dr. Perfect is Director of the NAID-sponsored Duke University Mycology Research Unit, which applies an interdisciplinary research approach to investigate the pathology of medically important fungi through the model pathogen, Cryptococcus neoformans. Dr. Perfect also serves as an attending physician for the DUMC Infectious Diseases consult service and maintains an active Infectious Diseases clinic. Dr. Perfect leads the Antibiotic Trials Unit, which has conducted over 50 clinical trials in the past ten years at DUMC. He is also a member of the Antibiotic Evaluation Team and Pharmacy & Therapeutics Committee at DUMC as well as a member of the American Society of Microbiology, Infectious Diseases Society of America, and the American Federation of Clinical Research. Dr. Perfect is a nationally recognized speaker and author of over 250 publications in the area of medical mycology.

Pranatharthi H. Chandrasekar, MD
Pranatharthi Haran Chandrasekar, MD is Professor of Medicine, Division of Infectious Diseases, Department of Internal Medicine, Wayne State University School of Medicine, Detroit, Michigan. Since 1993, he has also been a member of the Medical Advisory Committee at Harper University Hospital and Program Director of the Infectious Diseases Fellowship at Wayne State University. Currently, Dr. Chandrasekar serves on the Medical Advisory Board for Renaissance Home Health Care, in which he has participated since 1997. This year, he also serves on the Pharmacy and Therapeutics Committee at Detroit Medical Center, Department of Hematology/Oncology.

Dr. Chandrasekar belongs to several major professional societies. He is a Fellow of the American College of Physicians and the Infectious Diseases Society of America, and a member of the American Society of Microbiology and the International Immunocompromised Host Society. He has been involved in the Meet-The-Professor Sessions at the Annual Meeting of the Infectious Diseases Society of America and coordinated the Symposium on Nosocomial Infections, Christian Medical College and Hospital, Vellore, India. He has served as a reviewer of the Guidelines for the Prevention of Opportunistic Infections in Bone Marrow Transplant Recipients developed by the Department of Health and Human Services, Centers for Disease Control and Prevention, and also as a reviewer for the Project Outline Application for the Swiss National Science Foundation, 2000-2001. He has served as a reviewer for numerous peer-reviewed journals, including Antimicrobial Agents and Chemotherapy, Archives of Internal Medicine, Cancer, Clinical Infectious Diseases, European Journal of Clinical Microbiology/Infectious Diseases, Journal of Antimicrobial Chemotherapy, Journal of Respiratory Diseases, and Kidney International, among others.

Michael E. Kleinberg, MD, Ph.D.
Michael E. Kleinberg, MD, Ph.D. is Associate Professor of Infectious Diseases and Internal Medicine at the University of Maryland Greenebaum Cancer Center, Baltimore, Maryland. His major research interests are treatment of infections in neutropenic cancer patients and the role of neutrophil-generated oxidants in host defense and inflammation.

He received his bachelors degree from the State University of New York at Stony Brook and his masters, MD, and Ph.D. degrees from the Albert Einstein College of Medicine. Dr. Kleinberg completed his internal medicine residency training at Cornell University Medical Center/The New York Hospital and an Infectious Diseases fellowship at the National Institute of Health in Bethesda, Maryland. Dr. Kleinberg has been affiliated with the University of Maryland School of Medicine since 1990, where he has received NIH, VA, foundation, and pharmaceutical company grants for his basic science and clinical research. He is currently Director, Infectious Diseases section at the University Of Maryland Greenebaum Cancer Center. Dr. Kleinberg has been author or coauthor of numerous publications and has presented at educational forums in the United States and Europe.

Kieren A. Marr, MD
Kieren A. Marr, MD, is currently an Assistant Member at the Fred Hutchinson Cancer Research Center and an Assistant Professor of Medicine at the University of Washington in Seattle, Washington. Her research is focused on Aspergillus pathogenesis, and prevention and early diagnosis of invasive mould infections in immunocompromised patients. She was trained in microbiology at California State University and subsequently investigated toxoplasmosis and EBV-associated lymphoma in laboratories at Stanford and the National Institutes of Health. She received her MD degree from Hahnemann University, and completed her internship and residency in Internal Medicine at Duke University, where she also served as Assistant Chief Resident. She performed infectious diseases training at the University of Washington. Dr. Marr has received a number of honors during her training, including a Cancer Federation Award, the American Medical Woman's Association Citation, Membership to Alpha Omega Alpha, and the National Federation of Infectious Diseases Medical Mycology Fellowship. She currently serves on the program committee of the Infectious Diseases Society of America, the Council of the Immunocompromised Host Society, and multiple editorial boards.

Thomas J. Walsh, MD
Thomas J. Walsh, MD is a Senior Investigator and Chief of the Immunocompromised Host Section in the Pediatric Oncology Branch of National Cancer Institute, Bethesda, Maryland. He also serves in adjunct faculty positions at the University of Maryland School of Medicine and the John Hopkins University School of Medicine. Dr. Walsh directs a combined laboratory and clinical translational research program that is dedicated to the investigation of the antifungal pharmacology and chemotherapeutics, augmentation of host defenses, and molecular detection of invasive fungal infections in immunocompromised children and adults with cancer, stem cell transplantation, and other immunodeficiencies. Dr. Walsh received his medical degree from The John Hopkins University School of Medicine in Baltimore, Maryland. During the next ten years, he completed post-doctoral training with fellowships in Pathology, Infectious Diseases, and Medical Oncology with a central research focus on medical mycology. He was the first recipient of the Janssen Medical Mycology Fellowship from the National Foundation for Infectious Diseases. Dr. Walsh is board certified in Medicine, Infectious Diseases, and Oncology. His professional memberships include Councilor of the International Immunocompromised Host Society (ICHS), Co-Chair of the ICHS Medical Mycology Training Initiative, President-elect of the Medical Mycology Society of the Americas, Risk Group I Chair of the Bacteriology and Mycology Study Group, and Chair of the NCI Animal Care and Use Committee.

The recipient of numerous awards for his laboratory investigations and clinical research, Dr. Walsh has written extensively in the areas of diagnosis, pharmacology, Aspergillus, Candida, and selected emerging fungal pathogens, including Trichosporon, Scedosporium, Fusarium, and Zygomycetes. He also serves as reviewer or member of the editorial board of many leading journals, including the Annals of Internal Medicine, Antimicrobial Agents and Chemotherapy, Blood, Clinical Infectious Diseases, Infection and Immunity, Journal of Clinical Investigation, Journal of Clinical Microbiology, Journal of Clinical Oncology, Medical Mycology, Pediatric Infectious Diseases, The Journal of Infectious Diseases, The Lancet, and The New England Journal of Medicine. Over the past 15 years, Dr. Walsh has trained and mentored more than 70 research fellows and students from 16 different countries. For his teaching and mentoring, he has been named the recipient of the NIH Distinguished Clinical Teacher Award, the NCI Equal Employment Opportunity Award, and the NCI Mentor Award.

John R. Perfect, MD
John R. Perfect, MD has no actual or potential conflict of interest in relation to this program or presentation.

Pranatharthi H. Chandrasekar, MD
Pranatharthi H. Chandrasekar, MD has received research support from Pfizer, Inc. and serves on the Speakers' Bureau for Enzon Pharmaceuticals, Inc.; Merck & Co., Inc.; and Pfizer, Inc.

Michael E. Kleinberg, MD, Ph.D.
Michael E. Kleinberg, MD, Ph.D. is a consultant for Enzon Pharmaceuticals, Inc. and serves on the Speakers' Bureau; he also serves on the Speakers' Bureau for Pfizer, Inc. and has received research funding from Pfizer, Inc.

Kieren A. Marr, MD
Kieren A. Marr, MD has received grants or research support from Bio-Rad Laboratories; Merck & Co, Inc.; Ortho Biotech, Inc.; and Pfizer, Inc. Dr. Marr also serves as a consultant for Bio-Rad Laboratories; Bristol-Myers Squibb Company; CombinatorRx; Enzon Pharmaceuticals, Inc.; Inhale; Merck & Co., Inc.; Ortho Biotech, Inc.; Pfizer, Inc.; and Schering-Plough, Inc.

Thomas J. Walsh, MD
Thomas J. Walsh, MD has cooperative research and development agreements with Merck & Co., Inc., and Fujisawa Healthcare.